Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"W. L. Gore & Associates","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$320.0 million","newsHeadline":"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ViaCyte Inc

    Menu

    ViaCyte Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ViaCyte Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

              Details:

              The acquisition of ViaCyte provides Vertex with complementary assets including VC-02, and technologies including additional human stem cell lines, intellectual property around stem cell differentiation, and GMP manufacturing facilities for cell-based therapies.

              Lead Product(s): VC-02

              Therapeutic Area: Endocrinology Product Name: VC-02

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

              Deal Size: $320.0 million Upfront Cash: $320.0 million

              Deal Type: Acquisition July 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ViaCyte Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes

              Details:

              The Company is currently advancing a Phase II clinical study on its product candidate PEC-Encap. PEC-Encap (VC-01) is drug-device combination, where PEC-01 cells are loaded into an Encaptra drug delivery System.

              Lead Product(s): Encapsulated Pancreatic Islet Precursor Cells

              Therapeutic Area: Endocrinology Product Name: PEC-Encap

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Bain Capital Life Sciences

              Deal Size: $115.0 million Upfront Cash: Undisclosed

              Deal Type: Series D Financing June 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ViaCyte Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions

              Details:

              VC-02 is designed to enable production of both insulin and glucagon to modulate blood glucose, improve time in range, and ameliorate or prevent complications associated with type 1 diabetes. Phase 2 clinical studies to evaluate the safety and efficacy of VC-02 are ongoing.

              Lead Product(s): PEC-01 Cell

              Therapeutic Area: Endocrinology Product Name: VC-02

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ViaCyte Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

              Details:

              Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.

              Lead Product(s): Stem cell-derived pancreatic islet cell progenitors

              Therapeutic Area: Endocrinology Product Name: PEC-Encap

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: W. L. Gore & Associates

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY